Skip to main content

Table 4 Total and infant sex-stratified adjusted models of androgen levels and 12- and 36-month outcomes

From: Umbilical cord blood androgen levels and ASD-related phenotypes at 12 and 36 months in an enriched risk cohort study

Androgensa Subject sex Outcomes
   12-month AOSI 36-month SRS
   Beta 95% CI P P b Beta 95% CI P P b
ln(T) Female (n = 62) 0.20 (−0.13,0.53) 0.22 0.95 −0.05 (−0.31,0.20) 0.67 0.85
  Male (n = 75) 0.22 (−0.13,0.57) 0.22   0.14 (−0.19,0.46) 0.41  
ln(A4) Female (n = 62) 0.11 (−0.35,0.57) 0.64 0.90 −0.19 (−0.54,0.15) 0.27 0.89
  Male (n = 75) 0.05 (−0.37,0.47) 0.81   −0.17 (−0.55,0.21) 0.38  
ln(DHEA) Female (n = 62) 0.1 (−0.18,0.39) 0.48 0.74 −0.04 (−0.26,0.17) 0.70 0.84
  Male (n = 75) 0.02 (−0.31,0.36) 0.88   −0.01 (−0.31,0.32) 0.97  
  1. ln natural log transformed
  2. aRobust regression models of loge-transformed testosterone (T), androstenedione (A4), and dehydroepiandrostenedione (DHEA) with total loge (AOSI + 1) and loge (SRS raw) adjusted for gestational age and maternal age. Outcome measures are 12-month Autism Observation Scales for Infants (AOSI) total score and 36-month Social Responsiveness Scale (SRS) total raw score
  3. bInteraction P value comes from a model including both subject sexes including covariates, hormone variable, and subject sex hormone interaction